Semaglutide Microspheres High Drug Loading for Reduced Injection Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of semaglutide, a GLP-1 agonist, face challenges such as low bioavailability, high doses required for oral administration, and significant pain and inflammatory responses during self-administration of sustained-release microspheres.
Innovation Solution
A pharmaceutical composition comprising sustained-release microspheres with a high content of semaglutide (at least 8 wt%) and a bioavailability enhancer, combined with a biodegradable polymer, to achieve enhanced bioavailability and stable long-term drug release with reduced initial release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If semaglutide is encapsulated in microparticles made of biodegradable polymers for long-term release, then long-term effective pharmacological effects are achieved, but a large number of microspheres must be administered which causes severe pain and inflammatory response at the administration site
Solution Approach 1:
The patent changes the key parameter of drug content concentration within the microspheres. By formulating microspheres with high semaglutide content (5-20 wt%, preferably 10-15 wt%), the patent reduces the total number of microspheres needed for administration from thousands to a manageable amount (0.1-10 mg), thereby maintaining long-term release effects while minimizing pain and inflammatory responses at the injection site.
2Quantity of substance
If a large number of microspheres are administered to achieve long-term effective pharmacological effects, then sufficient drug delivery is achieved, but self-administration by patients becomes difficult
Solution Approach 1:
The patent optimizes the drug content parameter within microspheres to achieve high semaglutide concentration (5-20 wt%). This parameter change reduces the total microsphere quantity needed for effective drug delivery from large numbers to a small, patient-manageable amount (0.1-10 mg), enabling easy self-administration while maintaining sufficient pharmacological effects.
3Ease of operation
If oral administration is used for semaglutide, then patient compliance is improved, but bioavailability is much lower and significantly higher doses are required
Solution Approach 1:
The patent uses biodegradable polymer microspheres as an intermediary delivery system for semaglutide. This intermediary protects the peptide from enzymatic degradation in the gastrointestinal tract and facilitates absorption through the intestinal mucosa, thereby improving bioavailability while maintaining the convenience of oral administration for patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves high bioavailability of semaglutide, reducing the dosage needed and minimizing pain and inflammatory responses at the administration site, while providing sustained pharmacological effects for an extended period.
Implementation Method 1
sustained-release microspheres with a high content of semaglutide... combined with a biodegradable polymer, to achieve enhanced bioavailability and stable long-term drug release
Implementation Method 2
biodegradable polymer... stable long-term drug release with reduced initial release
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.